Research programme: antiviral immunostimulants - Kineta

Drug Profile

Research programme: antiviral immunostimulants - Kineta

Alternative Names: CB 183872; IB 657; rOAS-1

Latest Information Update: 28 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Illumigen Biosciences
  • Developer Kineta; KPI Therapeutics
  • Class Antivirals; Enzymes; Ligases; Proteins
  • Mechanism of Action Immunostimulants; Ribonuclease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Viral infections

Most Recent Events

  • 28 Aug 2018 No recent reports of development identified for preclinical development in Viral-infections in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Viral-infections in USA
  • 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top